



## PRESS RELEASE

### **Adocia to hold conference call for investors to provide business update and growth perspectives**

***Wednesday September 21<sup>st</sup>, 2016 at 6 PM (CET)***

**Lyon, September 19<sup>th</sup>, 2016** - Adocia (Euronext Paris: FR0011184241 - ADOC) will provide a business update for investors and growth perspectives on a conference call to be held:

**Wednesday September 21<sup>st</sup>, 2016**

**at 6pm (CET)**

***Dial-in number: +33 01 70 77 09 27***

*The transcript will be available in French and in English on Adocia's website*

[www.adocia.com](http://www.adocia.com)

Please note that the conference call will be held in French.

The following speakers will conduct the call:

- ✓ **Gérard Soula**, President and CEO
- ✓ **Olivier Soula**, R&D Director & Deputy General Manager
- ✓ **Valérie Danaguezian**, CFO
- ✓ **Rémi Soula**, Director of Business Development & Intellectual Property

## About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Glucagon), combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

*Adocia aims to deliver "Innovative medicine for everyone, everywhere."*

To learn more about Adocia, please visit us at [www.adocia.com](http://www.adocia.com)



## For more information please contact:

<b>Adocia</b> Gérard Soula Chairman and CEO <a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a> Tél. : +33 4 72 610 610	<b>Adocia Press Relations Europe</b> <b>MC Services AG</b> Raimund Gabriel <a href="mailto:adocia@mc-services.eu">adocia@mc-services.eu</a> Tél. : +49 89 210 228 0	<b>Adocia Investor Relations USA</b> <b>The Ruth Group</b> Tram Bui <a href="mailto:tbui@theruthgroup.com">tbui@theruthgroup.com</a> Tel.: +646.536.7035
--	---	--